Bridget Silverman
Senior Editor
Washington, D.C.
Bridget Silverman has been covering FDA for the Pink Sheet since David Kessler was commissioner. She keeps watch on the drug review process for the FDA Performance Tracker and the Drug Review Profile series. She covered FDA and financial beats as a Pink Sheet reporter before focusing on the drug development and approval process as an editor on Pharmaceutical Approvals Monthly and the NDA Pipeline, developing products that inform our current regulatory tracking features and in-depth FDA review coverage. In her down time, Bridget reads mystery novels and keeps track of her family and three dogs.
Latest From Bridget Silverman
Orphans Dominate New US FDA Approvals, Thanks To Rethymic, Tavneos, And Livmarli
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s October Outlook Includes Psoriasis Blockbuster Hopeful, Ophthalmology And Orphans
User fee goal dates are coming up in October for more than 15 applications, according to the Pink Sheet’s US FDA Performance Tracker.
Keeping Track: US FDA Is Approving JAK Inhibitors Again, Starting With Incyte’s Opzelura; Seagen’s Tivdak Cleared
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Keeping Track: Takeda’s Exkivity Clears US FDA; BeiGene’s Busy Summer
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Missed Review Deadlines Are Reminder That On-Time Approvals Are A Goal, Not A Guarantee
After more than a decade of sky-high rates of on-time regulatory action by the US FDA, missed user fee goal dates are back in a pretty big way – and it’s not just JAK inhibitor and COVID-19 delays.
Keeping Track: New Formulations Dominate In CNS; Immunocore Brings First TCR Therapy To US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.